FOR IMMEDIATE RELEASE
- Summit features specialized workshops and certification tracks alongside international faculty at the JW Marriott Cancun Resort & Spa
- Event is expected to draw more than 500 physicians, researchers, and regenerative medicine leaders to ISSCA’s flagship Cancun venue
- Global Summit contributes to ISSCA’s international education ecosystem and Global Stem Cells Group’s worldwide presence
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its 2026 Global Summit — ISSCA 125 — taking place September 25–27 at the JW Marriott Cancun Resort & Spa.
The Summit is expected to draw more than 500 physicians and professionals, with hundreds already registered, across specialized workshops and certification tracks including the organization’s flagship and peptide-medicine certifications, alongside international faculty, published authors, researchers, and physicians and leaders across regenerative medicine, longevity, and biotechnology.
ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries to date. The Global Summit is positioned as a flagship contribution to ISSCA’s international education ecosystem and Global Stem Cells Group’s broader global footprint.
“Cancun has become something of a home base for ISSCA’s most ambitious programming,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “The Global Summit is where physicians from the widest range of countries come together in one place, and that’s exactly the kind of international network effect we’re trying to build.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
